{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:21:40Z","timestamp":1777353700476,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03471-6","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T14:02:02Z","timestamp":1729951322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Secondary cutaneous malignancy after treatment of basal cell carcinoma with hedgehog pathway inhibitor: a systematic review"],"prefix":"10.1007","volume":"316","author":[{"given":"Christina M.","family":"Pierce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Howe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke A.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua L.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"issue":"2","key":"3471_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamadermatol.2013.1798","volume":"149","author":"S Aasi","year":"2013","unstructured":"Aasi S, Silkiss R, Tang JY, Wysong A et al (2013) New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol 149(2):242\u2013243. https:\/\/doi.org\/10.1001\/jamadermatol.2013.1798","journal-title":"JAMA Dermatol"},{"key":"3471_CR2","doi-asserted-by":"publisher","unstructured":"Aditya S, Aditya R, Vismodegib A smoothened inhibitor for the treatment of advanced basal cell carcinoma. Indian Dermatology Online J 4,4 (2013): 365\u2013368. https:\/\/doi.org\/10.4103\/2229-5178.12068","DOI":"10.4103\/2229-5178.12068"},{"issue":"4","key":"3471_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/bjd\/ljad206","volume":"189","author":"C Barrabes-Torrella","year":"2023","unstructured":"Barrabes-Torrella C et al (2023) Sarcomatoid transformation of a basal cell carcinoma following treatment with hedgehog inhibitors. Br J Dermatol 189(4):470\u2013472. https:\/\/doi.org\/10.1093\/bjd\/ljad206","journal-title":"Br J Dermatol"},{"issue":"10","key":"3471_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/DAD.0000000000001384","volume":"41","author":"B Bancalari","year":"2019","unstructured":"Bancalari B, Llombart B, Serra-Guill\u00e9n C (2019) Histologic changes during treatment with Vismodegib in locally advanced basal cell carcinoma: a Series of 19 cases. Am J Dermatopathol 41(10):711\u2013717. https:\/\/doi.org\/10.1097\/DAD.0000000000001384","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"3471_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jaad.2017.03.038","volume":"77","author":"T Bhutani","year":"2017","unstructured":"Bhutani T, Abrouk M, Sima CS et al (2017) Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol 77(4):713\u2013718. https:\/\/doi.org\/10.1016\/j.jaad.2017.03.038","journal-title":"J Am Acad Dermatol"},{"key":"3471_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jdcr.2023.12.001","volume":"44","author":"BA Burgess","year":"2024","unstructured":"Burgess BA, Wang RJ, Owen JL (2024) Same-site transdifferentiation of basal cell carcinoma to squamous cell carcinoma as a mechanism of vismodegib treatment resistance: two cases requiring multimodal and multidisciplinary limb-sparing techniques. JAAD Case Rep 44:17\u201319. https:\/\/doi.org\/10.1016\/j.jdcr.2023.12.001","journal-title":"JAAD Case Rep"},{"issue":"7","key":"3471_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/DSS.0000000000001059","volume":"43","author":"ALS Chang","year":"2017","unstructured":"Chang ALS (2017) Commentary on development of basal cell carcinoma with squamous differentiation during Vismodegib Treatment. Dermatol Surg 43(7):991\u2013992. https:\/\/doi.org\/10.1097\/DSS.0000000000001059","journal-title":"Dermatol Surg"},{"key":"3471_CR8","doi-asserted-by":"publisher","unstructured":"Chen L, Silapunt S, Migden MR (2016) Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Future Oncology; 12(18), 2095\u20132105. https:\/\/doi.org\/10.2217\/fon-2016-0118","DOI":"10.2217\/fon-2016-0118"},{"issue":"10","key":"3471_CR9","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1038\/s41433-020-01291-2","volume":"35","author":"DS Curragh","year":"2021","unstructured":"Curragh DS, Huilgol SC, Selva D (2021) Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma. Eye (Lond) 35(10):2740\u20132745. https:\/\/doi.org\/10.1038\/s41433-020-01291-2","journal-title":"Eye (Lond)"},{"issue":"7","key":"3471_CR10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/DSS.0000000000001012","volume":"43","author":"L Feigenbaum","year":"2017","unstructured":"Feigenbaum L, Scott BL, Moye MS, Nijhawan RI (2017) Development of basal cell carcinoma with squamous differentiation during Vismodegib Treatment. Dermatol Surg 43(7):989\u2013991. https:\/\/doi.org\/10.1097\/DSS.0000000000001012","journal-title":"Dermatol Surg"},{"key":"3471_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000537817","volume":"16","author":"N Ferrin","year":"2024","unstructured":"Ferrin N, Edmond D, Jones R, McCahill LE (2024) Management of locally advanced basal cell carcinoma with sonic hedgehog pathway targeted therapy: a case report and discussed. Case Rep Dermatol 16:75\u201382. https:\/\/doi.org\/10.1159\/000537817","journal-title":"Case Rep Dermatol"},{"issue":"12","key":"3471_CR12","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","volume":"131","author":"HS Gill","year":"2013","unstructured":"Gill HS, Moscato EE, Chang AL, Soon S, Silkiss RZ (2013) Vismodegib for periocular and orbital basal cell carcinoma. JAMA Ophthalmol 131(12):1591\u20131594. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.5018","journal-title":"JAMA Ophthalmol"},{"key":"3471_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ejca.2017.11.031","volume":"91","author":"R Giuffrida","year":"2018","unstructured":"Giuffrida R, Kashofer K, Dika E, Patrizi A, Baraldi C, Meo N, Zalaudek I (2018) Fast growing melanoma following treatment with vismodegib for locally advanced basal cell carcinomas: report of two cases. Eur J Cancer 91:177\u2013179. https:\/\/doi.org\/10.1016\/j.ejca.2017.11.031","journal-title":"Eur J Cancer"},{"issue":"6","key":"3471_CR14","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/DSS.0000000000000716","volume":"42","author":"D Guo","year":"2016","unstructured":"Guo D, Kossintseva I, Leitenberger J (2016) Neoadjuvant Vismodegib before Mohs: lack of tissue sparing and squamous differentiation of basal cell carcinoma in a patient with chronic lymphocytic leukemia. Dermatol Surg 42(6):780\u2013783. https:\/\/doi.org\/10.1097\/DSS.0000000000000716","journal-title":"Dermatol Surg"},{"issue":"1","key":"3471_CR15","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.jaad.2013.01.023","volume":"69","author":"A Iarrobino","year":"2013","unstructured":"Iarrobino A, Messina JL, Kudchadkar R, Sondak VK (2013) Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. J Am Acad Dermatol 69(1):e33\u2013e34. https:\/\/doi.org\/10.1016\/j.jaad.2013.01.023","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3471_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.25251\/skin.6.6.1","volume":"6","author":"J Ingrassia","year":"2022","unstructured":"Ingrassia J, Maher J, Cline AA (2022) Review of the risk of cutaneous squamous cell carcinoma after Vismodegib Therapy. SKIN J Cutan Med 6(6):453\u2013457. https:\/\/doi.org\/10.25251\/skin.6.6.1","journal-title":"SKIN J Cutan Med"},{"issue":"1","key":"3471_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/1941126X.2018.1444339","volume":"30","author":"N Johnson","year":"2016","unstructured":"Johnson N, Phillips M (2016) Rayyan for systematic reviews. J Electron Resour Librariansh 30(1):46\u201348","journal-title":"J Electron Resour Librariansh"},{"issue":"6","key":"3471_CR18","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jid.2023.10.040","volume":"144","author":"AR Jussila","year":"2024","unstructured":"Jussila AR, Haensel D, Gaddam S, Oro AE (2024) Acquisition of drug resistance in basal cell nevus syndrome tumors through basal to squamous cell carcinoma transition. J Invest Dermatol 144(6):1368\u20131377e6. https:\/\/doi.org\/10.1016\/j.jid.2023.10.040Epub 2023 Dec 28","journal-title":"J Invest Dermatol"},{"issue":"10","key":"3471_CR19","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamadermatol.2016.2429","volume":"152","author":"S Li","year":"2016","unstructured":"Li S, Chang AL (2016) Study on the risk of cutaneous squamous cell Carcinoma after Vismodegib Therapy for basal cell carcinoma-reply. JAMA Dermatol 152(10):1173. https:\/\/doi.org\/10.1001\/jamadermatol.2016.2429","journal-title":"JAMA Dermatol"},{"issue":"1","key":"3471_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jdcr.2018.09.016","volume":"5","author":"J Magdaleno-Tapial","year":"2018","unstructured":"Magdaleno-Tapial J, Valenzuela-O\u00f1ate C, Ortiz-Salvador JM et al (2018) Pilomatricomas secondary to treatment with vismodegib. JAAD Case Rep 5(1):12\u201314 Published 2018 Dec 4. https:\/\/doi.org\/10.1016\/j.jdcr.2018.09.016","journal-title":"JAAD Case Rep"},{"issue":"12","key":"3471_CR21","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1001\/archderm.136.12.1524.[36]","volume":"136","author":"I Marcil","year":"2000","unstructured":"Marcil I, Stern RS (2000) Risk of developing a subsequent nonmelanoma skin Cancer in patients with a history of nonmelanoma skin Cancer. Arch Dermatol 136(12):1524\u20131530. https:\/\/doi.org\/10.1001\/archderm.136.12.1524.[36]","journal-title":"Arch Dermatol"},{"key":"3471_CR22","doi-asserted-by":"publisher","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C (2015) PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75, 40\u201346. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.01.021","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"issue":"5","key":"3471_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","volume":"152","author":"SV Mohan","year":"2016","unstructured":"Mohan SV, Chang J, Li S, Henry AS, Wood DJ, Chang AL (2016) Increased risk of cutaneous squamous cell Carcinoma after Vismodegib Therapy for basal cell carcinoma. JAMA Dermatol 152(5):527\u2013532. https:\/\/doi.org\/10.1001\/jamadermatol.2015.4330","journal-title":"JAMA Dermatol"},{"key":"3471_CR24","unstructured":"National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Basal Cell Carcinoma. Version 3.2024. Accessed Oct 3"},{"key":"3471_CR25","unstructured":"National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Squamous Cell Carcinoma. Version 1.2024. Accessed Oct 3"},{"issue":"11","key":"3471_CR26","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3390\/ph6111429","volume":"6","author":"KE O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly KE, Vega-Saenz de Miera E, Segura MF et al (2013) Hedgehog pathway blockade inhibits melanoma cell growth in vitro and in vivo. Pharmaceuticals (Basel) 6(11):1429\u20131450. https:\/\/doi.org\/10.3390\/ph6111429","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"3471_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bjd.12840","volume":"171","author":"A Orouji","year":"2014","unstructured":"Orouji A, Goerdt S, Utikal J, Leverkus M (2014) Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma. Br J Dermatol 171(2):431\u2013433. https:\/\/doi.org\/10.1111\/bjd.12840","journal-title":"Br J Dermatol"},{"key":"3471_CR28","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed 372:n71. https:\/\/doi-org.libproxy.uthscsa.edu\/10.1136\/bmj.n71","journal-title":"BMJ (Clinical Res ed"},{"issue":"2","key":"3471_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000368350","volume":"230","author":"N Poulalhon","year":"2015","unstructured":"Poulalhon N, Dalle S, Balme B, Thomas L (2015) Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib. Dermatology 230(2):101\u2013104. https:\/\/doi.org\/10.1159\/000368350","journal-title":"Dermatology"},{"issue":"10","key":"3471_CR30","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jamadermatol.2016.2428","volume":"152","author":"S Puig","year":"2016","unstructured":"Puig S, Sampogna F, Tejera-Vaquerizo A (2016) Study on the risk of cutaneous squamous cell Carcinoma after Vismodegib Therapy for basal cell carcinoma: not a case-control study. JAMA Dermatol 152(10):1172\u20131173. https:\/\/doi.org\/10.1001\/jamadermatol.2016.2428","journal-title":"JAMA Dermatol"},{"issue":"11","key":"3471_CR31","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMc1504261","volume":"373","author":"KJ Ransohoff","year":"2015","unstructured":"Ransohoff KJ, Tang JY, Sarin KY (2015) Squamous change in basal-cell carcinoma with Drug Resistance. N Engl J Med 373(11):1079\u20131082. https:\/\/doi.org\/10.1056\/NEJMc1504261","journal-title":"N Engl J Med"},{"issue":"5","key":"3471_CR32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/jdv.12526","volume":"29","author":"C Saintes","year":"2015","unstructured":"Saintes C, Saint-Jean M, Brocard A et al (2015) Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib. J Eur Acad Dermatol Venereol 29(5):1006\u20131009. https:\/\/doi.org\/10.1111\/jdv.12526","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3471_CR33","doi-asserted-by":"publisher","unstructured":"Sekulic A, Migden MR, Oro AE et al Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366,23 (2012): 2171\u20132179. https:\/\/doi.org\/10.1056\/NEJMoa111371","DOI":"10.1056\/NEJMoa111371"},{"key":"3471_CR34","doi-asserted-by":"publisher","unstructured":"Silverman D, Li M, Olencki T, Seim NB, Teknos TN, Kang SY (2021) Transformation of facial basal cell carcinoma to squamous cell carcinoma following vismodegib. Otolaryngol Case Rep 20. https:\/\/doi.org\/10.1016\/j.xocr.2021.100284","DOI":"10.1016\/j.xocr.2021.100284"},{"issue":"8","key":"3471_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/DAD.0000000000001849","volume":"43","author":"SDB Smith","year":"2021","unstructured":"Smith SDB, Clarke CN, Clark MA, Harker-Murray AK, Sokumbi O (2021) Xanthomatous dermal changes in a patient with locally advanced basal cell carcinoma treated using Vismodegib. Am J Dermatopathol 43(8):585\u2013587. https:\/\/doi.org\/10.1097\/DAD.0000000000001849","journal-title":"Am J Dermatopathol"},{"key":"3471_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jdcr.2022.07.032","volume":"28","author":"R Zhao","year":"2022","unstructured":"Zhao R, Wang B, Lowe L, Dlugosz A, Bichakjian CK (2022) Metastatic same-site squamous cell carcinoma arising during vismodegib therapy for basal cell carcinoma. JAAD Case Rep 28:54\u201357 Published 2022 Aug 10. https:\/\/doi.org\/10.1016\/j.jdcr.2022.07.032","journal-title":"JAAD Case Rep"},{"key":"3471_CR37","doi-asserted-by":"publisher","unstructured":"Zhao X, Ponomaryov T, Ornell KJ et al (2015 September) RAS\/MAPK activation drives resistance to smo inhibition, metastasis and tumor evolution in shh pathway-dependent tumors. Cancer Res 1(17):3623\u20133653. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2999-T","DOI":"10.1158\/0008-5472.CAN-14-2999-T"},{"issue":"9","key":"3471_CR38","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamadermatol.2014.583","volume":"150","author":"GA Zhu","year":"2014","unstructured":"Zhu GA, Sundram U, Chang AL (2014) Two different scenarios of squamous cell carcinoma within advanced basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. JAMA Dermatol 150(9):970\u2013973. https:\/\/doi.org\/10.1001\/jamadermatol.2014.583","journal-title":"JAMA Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03471-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03471-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03471-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T16:07:26Z","timestamp":1732205246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03471-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3471"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03471-6","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"716"}}